Table 5
Factors associated with adverse neonatal/fetal events in pregnant women with PVCs
| Characteristic | Adverse event, n=7 | No adverse events, n=46 | OR (95% CI) | OR (95% CI) |
| Age, years | 33±4 | 33±5 |
| 1.0 (0.90 to 1.2) |
| Nulliparity | 1 (14%) | 14 (30%) | 0.4 (0.04 to 3.4) | |
| Maximal PVC burden in pregnancy, % | 15.9±11.6 | 14.7±13.7 | 1.0 (0.96 to 1.1) | |
| Maximal PVC burden>10% | 4 (57%) | 21 (46%) | 1.6 (0.31 to 7.9) | |
| Adverse cardiac event | 1 (14%) | 5 (11%) | 1.4 (0.13 to 13.8) | |
| Beta-blocker therapy in pregnancy | 4 (57%) | 21 (46%) | 1.6 (0.31 to 7.9) | |
| Obstetric risk factors | 5 (71%) | 20 (43%) | 3.2 (0.57 to 18.5) |
PVC, premature ventricular contraction.